Siu, L., Even, C., Mesía, R., Daste, A., Krauss, J., Saba, N. F., … Fayette, J. (2018). A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR. In International Journal of Radiation Oncology*Biology*Physics (Vol. 100, pp. 1307–1307). Elsevier BV. https://doi.org/10.1016/j.ijrobp.2017.12.021

Siu, L., C. Even, R. Mesía, A. Daste, J. Krauss, N. F. Saba, L. Nabell, et al. “A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR.” In International Journal of Radiation Oncology*Biology*Physics, 100:1307–1307. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2017.12.021.

Siu L, Even C, Mesía R, Daste A, Krauss J, Saba NF, et al. A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2018. p. 1307–1307.

Siu, L., et al. “A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR.” International Journal of Radiation Oncology*Biology*Physics, vol. 100, no. 5, Elsevier BV, 2018, pp. 1307–1307. Crossref, doi:10.1016/j.ijrobp.2017.12.021.

Siu L, Even C, Mesía R, Daste A, Krauss J, Saba NF, Nabell L, Ready NE, Garcia IB, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Jarkowski A, Melillo G, Armstrong JM, Fayette J. A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2018. p. 1307–1307.